T3 (Liothyronine) for Weight Loss: Honest Evidence Review

T3 (liothyronine, brand name Cytomel) is a synthetic form of triiodothyronine, the active thyroid hormone. It is FDA-approved for hypothyroidism, not for weight loss. Using T3 to lose weight in someone with normal thyroid function is off-label, unsupported by trial evidence, and carries documented risks: atrial fibrillation (Sawin 1994 NEJM, Framingham cohort^[2]), accelerated bone loss and fracture (Blum 2015 JAMA meta-analysis^[3]), and loss of lean muscle alongside fat. The 2014 American Thyroid Association guidelines (Jonklaas et al^[4]) explicitly recommend against thyroid hormone use for weight management in euthyroid patients. The 2009 Kaptein systematic review^[1] — the single most cited paper on this question — concluded that thyroid hormone produces modest short-term weight loss in euthyroid people but largely as lean tissue, with a clearly unfavorable risk-benefit profile. Meanwhile, the FDA-approved GLP-1 weight-loss medications produced −14.9% (Wegovy in STEP-1^[7]) and −20.9% (Zepbound in SURMOUNT-1^[8]) of total body weight, with body-composition profiles that favor fat loss. T3 is not a weight-loss drug. Here is what the evidence actually shows.

The honest summary

• T3 (liothyronine) is FDA-approved for hypothyroidism only. The Cytomel label lists three indications: hypothyroidism (primary, secondary, tertiary), TSH suppression in select thyroid-cancer cases, and as a diagnostic adjunct. Weight loss is not on the label^[9].
• In euthyroid (normal-thyroid) adults, T3 produces short-term weight loss but largely as lean mass and water, not fat. Kaptein 2009 J Clin Endocrinol Metab systematic review^[1] — the canonical paper on this question — concluded the risk-benefit profile is unfavorable.
• Suppressing TSH with exogenous thyroid hormone carries a clinically meaningful atrial-fibrillation risk. The Sawin 1994 NEJM Framingham analysis^[2] showed a 3x higher 10-year AF incidence in adults age 60+ with suppressed TSH compared with normal TSH.
• Suppressed TSH from exogenous thyroid hormone is associated with increased fracture risk. The Blum 2015 JAMA meta-analysis^[3] (pooled n > 70,000) found a hazard ratio of about 1.36 for hip fracture in subclinical hyperthyroidism.
• The 2014 American Thyroid Association guidelines (Jonklaas et al^[4]) state that thyroid hormone should not be used for weight loss in euthyroid patients and that levothyroxine (LT4) monotherapy is the standard of care for hypothyroidism. The 2021 ATA/BTA/ETA consensus^[5] reinforces this position.
• T3 monotherapy is not recommended for hypothyroidism either. The Grozinsky-Glasberg 2006 meta-analysis^[6] found no clinical advantage of combined LT4+LT3 over LT4 alone, and the short half-life of T3 (~24 hours vs ~7 days for LT4) produces unstable hormone levels and unpredictable dosing.
• FDA-approved obesity medications produce far larger weight loss with documented body-composition data. STEP-1 semaglutide −14.9% at 68 weeks^[7]; SURMOUNT-1 tirzepatide −20.9% at 72 weeks^[8]. T3 has no comparable trial.

Why this article exists

“How to take T3 for weight loss” gets about 600 monthly Google searches in the US, with related queries (“T3 cycle for weight loss,” “Cytomel dosage bodybuilding cutting,” “liothyronine fat loss”) adding several thousand more. The query is almost entirely driven by bodybuilding-forum culture, where T3 is used during “cutting cycles” alongside anabolic steroids and beta-agonists like clenbuterol. There is also a smaller stream of legitimate confusion from patients whose primary-care doctor mentioned that they have “a slow thyroid” or borderline TSH and who are looking for a faster path to weight loss than diet and exercise.

Both groups deserve a direct answer. T3 is a prescription thyroid hormone with a narrow set of legitimate uses. Taking it to accelerate weight loss in someone with a normal thyroid is a poor trade: the weight loss is real but modest and largely from lean tissue and water, the cardiac and skeletal risks are real and dose-dependent, and the comparison category — FDA-approved obesity drugs — now includes interventions that produce 2–4x the weight loss with better body-composition profiles. This article walks through what T3 is, what it does in the body, what the guideline-quality evidence says, and what to do instead.

What T3 is and what it is approved for

The thyroid gland produces two hormones with metabolic activity: thyroxine (T4), which has four iodine atoms and is the predominant circulating form, and triiodothyronine (T3), which has three iodine atoms and is the biologically active form at the cellular receptor level. Tissues convert T4 to T3 locally as needed. About 80% of circulating T3 comes from peripheral deiodination of T4, not direct thyroid secretion.

Pharmaceutical T3 (liothyronine sodium, brand name Cytomel) is synthetic triiodothyronine. The FDA-approved indications on the current Cytomel label are^[9]:

1. Hypothyroidism — replacement therapy for an underactive thyroid, including primary (thyroid gland), secondary (pituitary), and tertiary (hypothalamic) causes. In practice, levothyroxine (T4) is the first-line replacement; T3 is added or used only in selected patients.
2. Pituitary TSH suppression — for treatment or prevention of certain types of euthyroid goiters and as adjunctive therapy in some thyroid-cancer regimens.
3. Diagnostic adjunct — in T3 suppression tests to differentiate suspected mild hyperthyroidism from thyroid autonomy (rarely used in modern practice).

Weight loss is not on the label. The Cytomel prescribing information explicitly states that thyroid hormones, including liothyronine, are not indicated for treatment of obesity. Larger doses may produce serious or life-threatening manifestations of toxicity, particularly when given with sympathomimetic amines (such as those used for anorectic effects). This warning has been on the US T3 label for decades.

The off-label bodybuilding use case

T3 entered the bodybuilding lexicon in the 1980s as part of contest-prep “cutting cycles.” The pitch on bodybuilding forums has stayed essentially the same since then: take T3 at 25–75 mcg/day (sometimes higher) for 4–8 weeks pre-contest, pair with anabolic steroids to offset muscle loss, layer in clenbuterol for additional thermogenesis, and accept the cardiac and metabolic consequences as “part of prep.” The intended effect is to push resting metabolic rate above what diet alone produces in someone already at low body fat, where further loss has slowed.

Three things about this use case are worth being explicit on:

• There is no published trial showing that exogenous T3 in euthyroid adults produces durable fat loss beyond what an equivalent caloric deficit achieves alone. The weight that comes off during a T3-augmented cut is a mix of fat, lean mass, glycogen-bound water, and gut contents. The body-composition data (DXA or 4-compartment model) supporting selective fat loss does not exist.
• The supraphysiologic doses commonly used (50–100 mcg/day) suppress endogenous TSH and put the user into a state of iatrogenic hyperthyroidism. This is the metabolic state Sawin 1994 NEJM^[2] and Blum 2015 JAMA^[3] documented as associated with atrial fibrillation and fracture.
• The “taper to avoid thyroid shutdown” protocol common in bodybuilding circles has no clinical basis. Suppressed TSH from exogenous T3 does recover when the medication is discontinued, generally within weeks to months, but the underlying assumption that gradual tapering is necessary to preserve thyroid function is not supported by endocrinology literature. The taper may smooth the rebound symptoms; it does not change the underlying physiology.

Mechanism: why T3 makes you lose weight, and why most of it is the wrong tissue

T3 binds nuclear thyroid hormone receptors in essentially every tissue in the body. Among many downstream effects, T3 increases resting metabolic rate by upregulating mitochondrial oxidative phosphorylation, increases protein turnover (synthesis and breakdown), increases lipolysis (fat breakdown), and increases beta-adrenergic sensitivity (so catecholamines produce a stronger thermogenic and cardiac response).

In a hyperthyroid state — whether endogenous (Graves disease) or iatrogenic (exogenous T3) — the canonical clinical picture includes weight loss, heat intolerance, tachycardia, tremor, anxiety, increased appetite, and proximal muscle weakness. The weight loss happens, but the composition is unfavorable: a substantial fraction comes from skeletal muscle and bone, not fat. Patients with untreated Graves disease lose weight while also losing lean mass and accelerating bone resorption — the two specific adverse outcomes that the AF and fracture literature documents.

The Kaptein 2009 systematic review^[1] aggregated the existing trial data on thyroid hormone for obesity. The conclusion is worth quoting in spirit: thyroid hormone does produce weight loss in euthyroid people in the short term, but the loss includes substantial lean tissue, the effect does not persist long-term in a way that justifies the cardiovascular and skeletal risks, and the practice cannot be recommended outside research settings. This was the evidence base in 2009 and remains substantially the same today — there has been no large randomized trial of T3 for obesity in the intervening years, and there is unlikely to be one given the modern obesity-pharmacotherapy landscape.

Cardiac risk: atrial fibrillation

The clearest signal of harm from exogenous thyroid hormone above the dose needed for euthyroid replacement is atrial fibrillation. Sawin 1994 NEJM^[2], a Framingham Heart Study cohort analysis of 2,007 adults age 60 and older followed for 10 years, found that adults with serum TSH below 0.1 mIU/L — the level produced by excessive thyroid hormone replacement or off-label T3 use — had approximately a 3-fold higher incidence of new atrial fibrillation compared with adults whose TSH was in the normal range. The 28% vs 11% 10-year incidence figure from this paper is the most-cited number in the endocrinology literature on this question and is the primary reason endocrinologists titrate thyroid hormone to the lowest effective dose and avoid TSH suppression unless there is a specific cancer indication.

AF is not a benign arrhythmia. It increases stroke risk roughly 5-fold without anticoagulation, increases all-cause mortality, and frequently requires lifelong anticoagulation once present. Reverting to sinus rhythm after the precipitating cause is removed is possible but not guaranteed. A bodybuilder in their thirties using T3 for an 8-week cycle is a different risk population than the Framingham cohort, but the underlying physiology — suppressed TSH, supraphysiologic free T3, increased beta-adrenergic sensitivity — is the same.

Skeletal risk: bone loss and fracture

Thyroid hormone is a direct stimulator of osteoclast activity (bone resorption). In the long-suppressed state, the result is accelerated bone turnover with a net loss of bone mineral density, particularly at cortical sites like the femoral neck and forearm.

Blum 2015 JAMA^[3] is the canonical meta-analysis of subclinical thyroid dysfunction and fracture risk. Aggregating 13 prospective cohorts and more than 70,000 participants, the analysis found a hazard ratio of approximately 1.36 for hip fracture in subclinical hyperthyroidism (suppressed TSH with normal free T4 or T3), and a hazard ratio of approximately 1.28 for any fracture. The signal was strongest at the lowest TSH levels, where the relative risk of hip fracture approached 1.8.

For a postmenopausal woman, this is a particularly unfavorable trade-off. For a young bodybuilder, the immediate fracture risk during an 8-week cycle is small, but repeated annual cycles over a decade do produce cumulative bone-density consequences that may not become symptomatic until much later. This is the long-tail risk that bodybuilding-forum protocols tend to dismiss.

The Endocrine Society and ATA position

The 2014 American Thyroid Association guidelines for the treatment of hypothyroidism (Jonklaas et al^[4]) are explicit on two questions relevant to this article:

• Thyroid hormone should not be used for weight loss in euthyroid patients. The guideline lists this as a strong recommendation against. The rationale is the combination of (a) modest effect, (b) cardiovascular and skeletal risks, and (c) absence of trial evidence supporting a favorable risk-benefit profile.
• Levothyroxine (LT4) monotherapy is the standard of care for hypothyroidism. T3 monotherapy is not recommended because of its short half-life (~24 hours vs ~7 days for LT4), unstable serum levels, and absence of evidence of clinical superiority. The Grozinsky-Glasberg 2006 meta-analysis^[6] pooled 11 randomized trials comparing LT4 alone vs LT4 + LT3 combination therapy and found no consistent advantage for the combination on quality of life, body weight, lipids, or symptoms.

The 2021 ATA/BTA/ETA consensus document on LT4/LT3 combination therapy^[5] updated this position modestly, allowing a clinical trial of LT4 + LT3 combination in specific patients with persistent symptoms on optimized LT4 monotherapy, but reiterated that combination therapy is not first-line and should not be used for weight management.

When T3 is actually appropriate

T3 has a legitimate role in endocrinology. The clinical settings where a thyroid specialist might prescribe T3 are:

• Selected patients with persistent symptoms on LT4 monotherapy, with normal TSH but lingering hypothyroid symptoms (fatigue, cognitive complaints, low mood), after exclusion of other causes. The 2021 consensus^[5] outlines this as a trial of combination therapy under endocrinology supervision.
• Post-thyroidectomy or post-radioactive-iodine ablation patients who do not convert T4 to T3 efficiently, where free T3 levels remain low despite adequate LT4 dosing.
• TSH-suppressive therapy for specific differentiated thyroid cancers, where intentional suppression of TSH below the normal range is part of the cancer-prevention protocol. This is a specialist decision that explicitly accepts the AF and bone-loss risk as the cost of recurrence-risk reduction.
• Myxedema coma — severe acute hypothyroidism with hemodynamic compromise, where intravenous T3 provides faster onset than LT4. This is an ICU-level use case.

In every one of these scenarios, the decision belongs to an endocrinologist with TSH and free T3/T4 monitoring, cardiovascular risk assessment, and bone-density follow-up. None of them involves weight loss as the indication.

What to do if you actually want to lose weight

The honest answer for someone considering T3 for weight loss is: the FDA-approved obesity medications produce 2–4x the weight loss with a body-composition profile that favors fat loss and a side-effect profile that, while real, does not include atrial fibrillation or accelerated bone loss as dose-dependent harms.

For someone with persistent fatigue, cold intolerance, dry skin, constipation, or unexplained weight gain who suspects a thyroid problem: the first step is a TSH test (and ideally free T4) from a primary-care or endocrinology provider. If TSH is elevated, levothyroxine replacement to a normal TSH will resolve the hypothyroidism-driven weight gain and the associated symptoms. Adding T3 on top of an adequate LT4 dose to push weight loss further is not supported by evidence and is what the ATA guideline specifically advises against.

For someone with normal thyroid function who wants to lose weight: the evidence-based options are sustained caloric deficit, resistance training to preserve lean mass, and FDA-approved obesity pharmacotherapy where indicated and accessible. The semaglutide and tirzepatide trial data establish what the current standard of care produces. See our GLP-1 + levothyroxine interaction article for the related question of how GLP-1 medications affect thyroid hormone absorption in patients already on replacement.

What the evidence does and doesn't say

What the T3 literature does say:

• T3 produces short-term weight loss in euthyroid adults at supraphysiologic doses, but body composition is unfavorable (lean mass and water loss are substantial; Kaptein 2009^[1]).
• Suppressed TSH from exogenous thyroid hormone is associated with a ~3-fold increase in atrial-fibrillation incidence in older adults (Sawin 1994^[2]).
• Subclinical hyperthyroidism is associated with a hazard ratio of about 1.36 for hip fracture (Blum 2015 meta- analysis^[3]).
• The ATA recommends against thyroid hormone for weight loss in euthyroid patients and supports LT4 monotherapy as the standard for hypothyroidism (Jonklaas 2014^[4]).
• LT4 + LT3 combination therapy does not show consistent advantages over LT4 alone on weight, lipids, or symptoms (Grozinsky-Glasberg 2006^[6]).

What the T3 literature does NOT say:

• There is no RCT showing that T3 in euthyroid adults produces selective fat loss preserving lean mass.
• There is no RCT showing that T3 is safe at the doses used in bodybuilding cutting cycles (50–100+ mcg/day).
• There is no evidence that gradual T3 tapering after a cycle prevents long-term thyroid dysfunction.
• There is no evidence that T3 produces comparable weight loss to FDA-approved obesity medications.

Bottom line

• T3 (liothyronine) is a prescription thyroid hormone approved for hypothyroidism, not weight loss. Using it off-label to accelerate weight loss in someone with normal thyroid function is unsupported by evidence and carries documented cardiac and skeletal risks.
• The weight loss T3 produces in euthyroid adults is real but modest, includes substantial lean tissue and water, and comes with atrial-fibrillation and fracture risk that scales with dose and duration.
• The 2014 ATA hypothyroidism guideline explicitly recommends against thyroid hormone use for weight management in euthyroid patients^[4].
• If you have symptoms suggesting hypothyroidism, get a TSH test. If it is elevated, levothyroxine replacement is the first-line treatment. Adding T3 for further weight loss is not the answer.
• For weight loss in a normal-thyroid patient, the evidence-based options are sustained caloric deficit, resistance training, and FDA-approved obesity pharmacotherapy — not thyroid hormone.
• FDA-approved GLP-1 obesity medications produced −14.9% (STEP-1^[7]) and −20.9% (SURMOUNT-1^[8]) total body-weight reductions in their pivotal trials. T3 has no comparable trial because it is not a weight-loss drug.

Related research and tools

• GLP-1 + levothyroxine (Synthroid) interaction — how semaglutide and tirzepatide affect thyroid hormone absorption in patients already on LT4 replacement
• Does GLP-1 cause thyroid cancer? Medullary thyroid carcinoma evidence — the separate question of GLP-1 thyroid-cancer signal vs the C-cell rodent data
• Does bupropion cause weight loss? — the parallel walkthrough for another off-label weight-loss agent with modest magnitude and meaningful safety constraints
• GLP-1 bone density and fracture risk — the related skeletal-risk question for GLP-1 medications
• Exercise pairing on a GLP-1 — the resistance-training half of the lean-mass preservation protocol
• GLP-1 protein calculator — daily protein target (1.6–2.0 g/kg) for lean-mass preservation during weight loss
• Semaglutide drug page and tirzepatide drug page — FDA-approved obesity pharmacotherapy options
• Why am I not losing weight on a GLP-1 (the plateau guide) — the evidence-based plateau workup

Important disclaimer. This article is educational and does not constitute medical advice. T3 (liothyronine) is a prescription medication with documented cardiovascular and skeletal risks at supraphysiologic doses and should be prescribed and monitored only by a qualified clinician for an FDA-approved indication. Do not start, stop, or change the dose of any thyroid medication without your prescribing clinician. Patients with established hypothyroidism on levothyroxine should have TSH retested and the dose titrated by their endocrinologist or primary-care provider, not by self-medication. Patients with persistent fatigue, weight gain, cold intolerance, or other suspected hypothyroid symptoms should have a TSH test before assuming any cause. Patients using T3 off-label for weight loss or bodybuilding who experience palpitations, irregular heartbeat, chest pain, shortness of breath, or new symptoms should seek urgent medical evaluation; atrial fibrillation can present subtly and increases stroke risk. PMIDs were independently verified against the PubMed E-utilities API on 2026-05-28.

Last verified: 2026-05-28. Next review: every 12 months, or sooner if the ATA hypothyroidism guideline or FDA Cytomel label is updated.